Pediatrix Medical Group, Inc. (NYSE:MD) Director Sells $423,660.00 in Stock

Pediatrix Medical Group, Inc. (NYSE:MD) Director Mark S. Ordan sold 27,600 shares of the stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total value of $423,660.00. Following the completion of the sale, the director now owns 138,683 shares in the company, valued at approximately $2,128,784.05. The trade was a 16.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Pediatrix Medical Group Price Performance

MD opened at $14.15 on Friday. Pediatrix Medical Group, Inc. has a 12 month low of $6.62 and a 12 month high of $16.41. The stock has a fifty day moving average price of $12.53 and a 200-day moving average price of $9.85. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.42 and a quick ratio of 1.42.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings results on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. The business had revenue of $511.20 million for the quarter, compared to analysts’ expectations of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The company’s revenue was up .9% compared to the same quarter last year. During the same period last year, the business earned $0.29 EPS. As a group, equities research analysts expect that Pediatrix Medical Group, Inc. will post 1.25 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Mizuho increased their target price on Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a research note on Monday, November 4th. Truist Financial lifted their price objective on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a report on Monday, November 4th. Jefferies Financial Group boosted their price objective on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. UBS Group raised their target price on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a report on Monday, November 4th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $16.10.

Institutional Trading of Pediatrix Medical Group

Several hedge funds and other institutional investors have recently made changes to their positions in the business. nVerses Capital LLC purchased a new stake in Pediatrix Medical Group in the second quarter valued at about $31,000. Innealta Capital LLC acquired a new stake in Pediatrix Medical Group in the 2nd quarter worth approximately $33,000. Quest Partners LLC grew its position in Pediatrix Medical Group by 25.6% during the 3rd quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock worth $35,000 after purchasing an additional 622 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in Pediatrix Medical Group by 47.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock valued at $36,000 after purchasing an additional 1,524 shares in the last quarter. Finally, Quarry LP increased its stake in Pediatrix Medical Group by 54.1% during the 3rd quarter. Quarry LP now owns 4,735 shares of the company’s stock valued at $55,000 after purchasing an additional 1,662 shares in the last quarter. Hedge funds and other institutional investors own 97.71% of the company’s stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.